Transgene Reports 2015 Financial Results and Provides Outlook for 2016

information fournie par Boursorama •08/03/2016 à 18:00

Transgene Reports 2015 Financial Results and Provides Outlook for 2016

• Solid financial position:
- 2015 year-end cash available of ?31.7 million, plus up to ?30 million in additional financing secured in January 2016

• Implementation of new development strategy underway:
- Ambitious development plan with Transgene’s immunotherapy product candidates in combination with immune checkpoint inhibitors

Conference call and webcast (in English) March 9 at 2:30pm CET (I:30pm GMT/8:30am EST)


Strasbourg, France, March 8, 2016 – Transgene SA (Euronext: TNG) today announced its financial results for the fiscal year ended December 31, 2015 and provided an outlook for 2016.

Financial Year 2015 highlights:

• Net cash burn for 2015 decreased by 22.5% to ?34.8 million, versus ?44.9 million in 2014
• Cash available at year-end 2015 were ?31.7 million compared to ?65.9 million at year-end 2014
• R&D expenses of ?32.1 million compared to ?41.7 million in 2014
• Restructuring costs of ?7.5 million in 2015
• Net loss of ?46.4 million in 2015, including restructuring costs, compared to ?48.6 million in 2014